Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The MI-CLAIM checklist has been revised to take account of new capabilities of large language models and other generative artificial intelligence tools.
Transparent and mandatory feedback-collection mechanisms should be integrated into AI-enabled digital health technology interfaces for holistic development and patient safety.
A method designed to account for data gaps and under-reporting estimates 64,260 deaths from traumatic injury — indicating that prior reports underestimated by 41%.
GroceryDB uses machine learning to categorize the degree of processing of over 50,000 food items in US stores — and guides consumers toward healthier choices through accessible data.
Clinical research should recruit participants from LGBTQIA+ populations, and this requires specific actions and policies to create affirming and welcoming environments.
Brian J. Druker describes how his research on imatinib validated protein kinases as therapeutic targets for cancer and led to a life-saving treatment for leukemia.
Announced in this Comment and in collaboration with Nature Medicine is the convening of the Access to Dialysis in Low- and Middle-Income Countries Commission, which will explore Thailand’s experiences with changing its dialysis coverage policy, offering lessons for other countries with universal health coverage systems.
Announced in this Comment and in collaboration with Nature Medicine is the convening of the Quality Health Information for All Commission, to promote equitable access to quality health information from trusted sources and affirm the practice of health communication as a distinct public health discipline.
Our Future Health has recruited more than 1 million participants in the UK, with biobanked bloods, making it the largest consented cohort of its type in the world.
A study detected hidden cancers in almost half of all pregnant people who were referred for cancer screening following an abnormal or unreportable prenatal blood test result.
According to preclinical studies and a retrospective clinical analysis, the menstrual cycle may influence the breast cancer response to neoadjuvant chemotherapy — suggesting that treatment could be timed for optimal outcomes.
